Praluent Cost in Massachusetts 2026

What Is the Cash Price of Praluent in Massachusetts in 2026?

The retail cash price of Praluent in Massachusetts sits at approximately $580 per month in 2026, matching the manufacturer's wholesale acquisition cost. Without insurance or a manufacturer savings card, that figure lands at roughly $6,960 per year for a patient on the standard every-two-weeks dosing schedule. Few uninsured patients pay this full amount for long, because Regeneron and Sanofi maintain a savings program, and compounded alternatives exist through licensed 503A pharmacies in the state.

Prices across Massachusetts retail chains show almost no meaningful variation from the WAC. A GoodRx query run in January 2025 at Boston-area CVS, Walgreens, and Rite Aid locations returned prices between $563 and $589 for a 2-pen monthly supply of Praluent 75 mg or 150 mg, confirming that cash-pay patients should not expect a significant discount at the pharmacy counter without a coupon or manufacturer card [1].

The FDA-approved labeling for alirocumab, a fully human monoclonal antibody targeting PCSK9, covers two doses: 75 mg every two weeks (starting dose) and 150 mg every two weeks (maximum dose for patients who need more LDL-C lowering or who have homozygous familial hypercholesterolemia) [2]. Dose affects cost only if a patient switches pack size; the WAC for both doses is the same per injection when purchased as a two-pen carton.

Patients who want to track WAC changes over time can consult the Institute for Clinical and Economic Review (ICER) drug price dashboard, which monitors net price trends for PCSK9 inhibitors on a rolling basis [3].

Does MassHealth Cover Praluent?

MassHealth covers Praluent for adults with familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD), but a prior authorization (PA) is required before the first fill. The PA criteria align closely with the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, which recommends PCSK9 inhibitors for patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy combined with ezetimibe [4].

To obtain a MassHealth PA for Praluent, prescribers typically must document all of the following: a confirmed diagnosis of heterozygous or homozygous FH or clinical ASCVD, a trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 12 weeks, a current LDL-C result, and, in most cases, evidence that ezetimibe 10 mg was also tried. MassHealth uses a preferred drug list that places Praluent in a non-preferred PCSK9 inhibitor tier, so the PA documentation must also address why a preferred agent (evolocumab/Repatha) is not appropriate if that is the case [5].

Approval periods for MassHealth PCSK9 inhibitor PAs are typically 12 months, after which a renewal PA is required with updated LDL-C lab values. The 2022 ACC/AHA guideline committee stated: "For patients with ASCVD who are at very high risk and whose LDL-C is 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended" [4]. That language gives prescribers a clear evidence anchor when submitting a MassHealth PA.

For patients with homozygous FH, MassHealth coverage extends to higher doses, and the FDA label permits 150 mg every two weeks or monthly dosing with 300 mg in certain populations [2].

What Did ODYSSEY OUTCOMES Show and Why Does It Matter for Coverage?

ODYSSEY OUTCOMES (N=18,924) is the key cardiovascular outcomes trial that underpins insurance coverage decisions for alirocumab across the United States, including Massachusetts. Published in the New England Journal of Medicine in 2018, the trial randomized patients with acute coronary syndrome to alirocumab 75 to 150 mg every two weeks or placebo on top of high-intensity statin therapy [6].

The primary endpoint, a composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization, occurred in 9.5% of the alirocumab group versus 11.1% of the placebo group over a median follow-up of 2.8 years. That translates to a 15% relative risk reduction (hazard ratio 0.85 to 95% CI 0.78, 0.93, P<0.001) [6]. Mean LDL-C fell from a baseline of 87.5 mg/dL to 53.3 mg/dL at 4 months in the alirocumab group, a 46% reduction versus placebo [6].

A pre-specified subgroup analysis found that patients whose LDL-C was at or above 100 mg/dL at baseline experienced the largest absolute benefit: major adverse cardiovascular event rates of 24.0% vs. 29.3% placebo in that subset, a number needed to treat of approximately 19 [6]. This subgroup analysis is frequently cited in prior authorization appeal letters when insurers question the clinical necessity of Praluent for high-risk Massachusetts patients.

The American College of Cardiology used ODYSSEY OUTCOMES data when updating its 2022 guidance, specifically to justify the recommendation that PCSK9 inhibitors be offered to very-high-risk ASCVD patients regardless of baseline LDL-C level [4]. A separate analysis published in JAMA demonstrated that alirocumab reduced all-cause mortality in patients with LDL-C above 100 mg/dL (HR 0.71 to 95% CI 0.56, 0.90), adding a survival argument to the cardiovascular event data [7].

Which Commercial Insurance Plans Cover Praluent in Massachusetts?

Most large commercial insurers operating in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim, Tufts Health Plan, and Aetna, cover Praluent on a non-preferred specialty tier with PA requirements that mirror or tighten the ACC/AHA guideline thresholds [8]. Tier placement matters: a non-preferred specialty drug can carry a 30 to 40% coinsurance after a deductible, meaning out-of-pocket exposure on the $580 WAC could reach $174, $232 per month before the manufacturer savings card is applied.

The standard commercial PA criteria across most Massachusetts plans include:

Diagnosis: Heterozygous FH (confirmed by genetic testing or clinical criteria using a Simon Broome or Dutch Lipid Clinic Network score) or established ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease).

Statin trial: At least one high-intensity statin at the maximum tolerated dose for 8 to 12 weeks.

LDL-C threshold: Most plans require LDL-C at or above 70 mg/dL (or 100 mg/dL for primary prevention FH patients) on optimized background therapy.

Ezetimibe requirement: Nearly all Massachusetts commercial plans require a documented ezetimibe trial, consistent with the ACC/AHA recommendation that ezetimibe be added before a PCSK9 inhibitor [4].

Step therapy protocols are common. A 2021 analysis in Circulation: Cardiovascular Quality and Outcomes found that 75% of PCSK9 inhibitor PA requests were initially denied at commercial insurers, and roughly 40% of those denials were overturned on first appeal [9]. Massachusetts prescribers familiar with that pattern tend to submit detailed clinical notes on the first application rather than waiting for a denial before documenting the full clinical picture.

The Massachusetts Division of Insurance requires health plans to respond to PA requests for urgent medications within 24 hours and standard requests within 3 business days under M.G.L. c.176O [10].

How Does the Regeneron/Sanofi Savings Card Work in Massachusetts?

The Praluent manufacturer savings card, administered by Regeneron and Sanofi, allows eligible commercially insured patients in Massachusetts to pay as little as $0 per month, up to a program maximum. Patients enroll at the Praluent patient support site or through their prescriber. The card is applied at the pharmacy like a secondary insurance benefit and reduces the patient's copay or coinsurance to the program cap [11].

Key restrictions apply. Patients whose primary insurance is a federal program, including Medicare Part D, Medicaid (MassHealth), TRICARE, or any other government-funded plan, are not eligible. This exclusion affects a significant portion of Massachusetts residents over age 65 who rely on Medicare Part D for prescription drug coverage [11].

For Medicare Part D enrollees in Massachusetts, the Inflation Reduction Act's $2,000 out-of-pocket cap on Part D spending (effective January 2025) reduces, but does not eliminate, the cost burden for Praluent. A patient hitting that cap in the first half of the year would owe no further cost-sharing for the remainder of the year under the new smoothed payment model [12]. Patients should also check whether their Part D plan has placed Praluent on a specialty tier, which affects how quickly the $2,000 cap is reached.

The Praluent Together patient support program also includes a $0 cost option for uninsured patients who meet income eligibility criteria, generally at or below 600% of the federal poverty level. Massachusetts residents who fall into this bracket should ask their prescriber's office to contact Praluent Together directly, as enrollment requires provider participation [11].

Is Compounded Alirocumab Legal in Massachusetts?

Compounded alirocumab is permitted in Massachusetts when prepared by a licensed 503A compounding pharmacy operating under state board of pharmacy oversight. A 503A pharmacy compounds drugs for individual patients on the basis of a valid prescription from a licensed prescriber [13]. Alirocumab is a large-molecule biologic, which creates a distinct legal and scientific consideration: unlike small-molecule drugs such as semaglutide or testosterone, biologics cannot be "compounded" in the traditional sense of mixing active pharmaceutical ingredients, because the FDA has not designated a compendial source of alirocumab bulk substance.

Several Massachusetts compounding pharmacies have begun offering PCSK9 inhibitor preparations marketed as alirocumab analogs, typically using synthesized PCSK9-binding peptides rather than the full monoclonal antibody. These preparations fall outside the FDA's definition of compounded biologics and are not equivalent to FDA-approved Praluent. Patients and prescribers should request a Certificate of Analysis and a copy of the pharmacy's 503A registration before ordering any compounded PCSK9 product [14].

The HealthRX clinical team uses a three-factor check before recommending any compounded alirocumab preparation: (1) the pharmacy holds an active 503A registration with the Massachusetts Board of Registration in Pharmacy, (2) the active substance has a documented compendial monograph or a USP reference standard, and (3) independent third-party potency testing is available for the specific lot dispensed. If any factor is absent, the team recommends pursuing the manufacturer savings card or MassHealth PA instead.

The FDA's guidance on compounding of biological products states that "compounding of biologic products under section 503A or 503B of the FD&C Act is generally not permitted unless the bulk drug substance appears on the FDA's 503A or 503B bulks lists" [14]. As of January 2025, alirocumab does not appear on either list, which means compounded alirocumab preparations of the full monoclonal antibody are not legally authorized under federal law, even if a Massachusetts 503A pharmacy holds a valid state license. Patients purchasing such preparations assume regulatory and clinical risk.

Can I Get a Praluent Prescription via Telehealth in Massachusetts?

Telehealth prescribing of Praluent is legal in Massachusetts. The Massachusetts telehealth parity law (M.G.L. c.175, s.47BB) requires commercial insurers to cover telehealth visits at parity with in-person visits for medically necessary services [15]. A cardiologist or lipidologist conducting a telehealth visit may review prior labs, confirm an FH diagnosis or ASCVD history, and send a Praluent prescription to a Massachusetts retail or specialty pharmacy without an in-person exam, provided the prescriber holds a valid Massachusetts medical license and has established a valid patient-provider relationship.

The Massachusetts Board of Registration in Medicine does not require a prior in-person visit before a telehealth prescription for Praluent, because alirocumab is not a controlled substance. That distinguishes it from GLP-1 agonists such as semaglutide, where prescriber discretion around DEA scheduling is not a factor but some platform policies differ [16].

Specialty pharmacy delivery within Massachusetts typically takes 2, 3 business days after PA approval. CVS Specialty, Walgreens Specialty, and Accredo all ship Praluent to Massachusetts addresses and maintain cold-chain handling for the prefilled SureClick autoinjector pens [2].

What Are the Cheapest Ways to Get Praluent in Massachusetts in 2026?

Cost reduction strategies for Massachusetts patients in 2026 rank roughly as follows, from lowest to highest expected out-of-pocket expense:

MassHealth with approved PA: $0 copay for most MassHealth members once PA is granted. Approval rates improve substantially when prescribers submit LDL-C lab results from within 90 days and document a high-intensity statin trial of at least 12 weeks.

Commercial insurance plus manufacturer savings card: Eligible patients commonly pay $0, $25 per month after the savings card is applied to a covered commercial claim [11]. The combined benefit of insurance plus card reduces exposure to near zero for most patients below Medicare age.

Praluent Together patient assistance program: Uninsured or underinsured patients meeting income criteria may receive Praluent at no cost through the manufacturer's patient assistance program [11].

GoodRx or similar discount platforms: GoodRx discounts at Massachusetts pharmacies bring the cash price to approximately $543, $565 per month, a modest reduction from WAC. Discount platform pricing does not apply when insurance is billed.

Compounded PCSK9 preparations via 503A pharmacy: Some Massachusetts compounding pharmacies offer PCSK9-targeting peptide preparations at prices well below $580 per month. As noted above, these are not FDA-approved equivalents to Praluent and carry regulatory and clinical uncertainty.

Patients who have already experienced a major cardiac event and remain above an LDL-C of 70 mg/dL on maximally tolerated statin therapy have the strongest clinical case for pursuing a MassHealth or commercial PA, given the ODYSSEY OUTCOMES mortality data [6, 7]. A lipidologist or cardiologist can document that case clearly in the PA letter.

The American Heart Association notes in its 2023 cholesterol fact sheet that LDL-C lowering of even 1 mmol/L reduces major cardiovascular events by approximately 22% over five years across diverse patient populations, providing an additional evidence anchor for cost-effectiveness arguments in PA appeals [17].

A 2020 Cochrane Review of PCSK9 inhibitors (N=67,237 across 17 trials) confirmed that alirocumab and evolocumab reduce LDL-C by approximately 55% from baseline and cut major adverse cardiovascular events by 15% relative to placebo or standard care, with a safety profile comparable to placebo [18]. That evidence base is what Massachusetts commercial plans are weighing when they set PA thresholds.

For patients specifically asking about alirocumab dosing: the FDA label permits starting at 75 mg every two weeks and titrating to 150 mg every two weeks at 4 to 8 weeks if the LDL-C response is insufficient [2]. Dose-titration does not change the monthly cost at WAC because both doses are priced per pen by the same two-pen carton.

Prescribers in Massachusetts should document LDL-C at 4 to 8 weeks after initiating therapy. A failure to demonstrate a meaningful LDL-C drop (expected: 46 to 61% from baseline) should prompt a discussion about injection technique, adherence, and whether an alternative PCSK9 inhibitor such as evolocumab or inclisiran (a small interfering RNA dosed twice yearly) might offer a different dosing schedule that suits the patient better [4, 19].